AB1055 COMORBIDITIES IN SPONDYLOARTHRITIS: DATA FROM THE MOROCCAN RBSMR REGISTRY

• Published in: Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 1749 - 1750
• Main Authors: Baba, Z, Mougui, A, Abouqal, R, Allali, F, Bahiri, R, Bezza, A, A EL Maghraoui, I El Ghozlani, Harzy, T, Hassikou, H, Hmamouchi, I, Linda, I, Janani, S, Niamane, R, I El Bouchti
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2023
• Subjects: Arthritis; Comorbidity; Diabetes; Diabetes mellitus; Disease; Dyslipidemia; Fibromyalgia; Hypertension; Inflammatory diseases; Metabolic disorders; Obesity; Osteoporosis; Psoriasis; Rheumatic diseases; Sex ratio; Smoking; Ulcers; Uveitis
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2023-eular.5962

BackgroundIn addition to the extra-articular manifestations associated with spondyloarthritis such as IBD, psoriasis and uveitis, spondyloarthritis is linked to an increased risk of comorbidities.ObjectivesTo study the prevalence of comorbidities in spondyloarthritis (SPA) at inclusion and 36-month follow-up and their influence on disease activity and functional outcome in a cohort of patients followed for SPA from the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry).MethodsData were analyzed from cohort of 194 patients with SPA from the RBSMR Registry including comorbidities (hypertension, diabetes, dyslipidemia, obesity, osteoporosis, sedentary lifestyle, gastrointestinal ulcer, smoking, depression, fibromyalgia) and disease activity scores at inclusion (M0) and at 36-month follow-up (M36).ResultsThe mean age was 40,23 ± 13,68 ans. The sex-ratio (M/W) was 1,73. 96.4 % of the patients had axial involvement, 70 % had peripheral involvement and 61.5 % had enthesitis. SPA was radiographic in 88.1 % of the cases. The mean duration of disease was 615,90 ± 349,12 weeks. 57,2% of patients had at least one comorbidity, among whom the median comorbidity count was 1 (range 1-5).Table 1.comparison between prevalence of comorbidities at M0 and M36.ComorbidityPrevalence at inclusion (M0)Prevalence at 36-month follow-up (M36)Sedentary behaviour29,4% (n=57)31,4% (n=61)Osteoporosis11,3% (n=22)13,4% (n=26)Smoking10,8% (n=21)10,8% (n=21)Hypertension5,7% (n=11)9,3% (n=18)Obesity8,2% (n=16)8,2% (n=16)Tuberculosis6,7% (n=13)11,34% (n=22)Diabetes5,2% (n=10)6,2% (n=12)Gastrointestinal ulcer2,6% (n=5)3,1% (n=6)Dyslipidemia1,5% (n=3)2,6% (n=5)Cancer0% (n=0)1,0%(n=2)Depression2,6% (n=5)2,6% (n=5)Fibromyalgia2,1% (n=4)2,1% (n=4)Table 2.Comparison between patients with or without comorbidities.ParameterPatients with at least one comorbidity (57,2%)Patients without comorbidities (42,8%)pESR (mm/h)36,2436,970,163CRP (mg/l)42,1427,000,002ASDAS-CRP3,672,500,003BASDAI5,104,500,098BASFI6,104,160,028ConclusionIn our study, the presence of comorbidities was correlated with more severe disease activity. Better management of these comorbidities may result in better outcome of patients with SPA.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.